NDS-ECNW obtains patent for Trimoxi injectable formulation
NDS-ECNW has obtained a U.S. patent for its Trimoxi injectable formulation for prophylaxis after cataract surgery, according to a press release.
“Our core formula is highly tunable with any ophthalmic NSAID, with almost all classes of topical antibiotics, including well-known fourth-generation fluoroquinolone, and the varying strength corticosteroids like prednisolone, difluprednate and triamcinolone,” Scott Karolchyk, MSc, executive vice president and chief formulation pharmacist at NDS-ECNW, said in the release.
Source: Adobe Stock.
NDS-ECNW plans to submit its Trimoxi formulation for FDA approval under the 505(b)(2) pathway.
“Manufacturing of these products is efficient and inexpensive, a single production process with automated equipment creating multiple formulations for injection and topical delivery,” Karolchyk said. “The suspension’s particle size is smaller than a human red cell so it won’t clog the dispensing bottle or contain toxic preservatives like [benzalkonium chloride], and patients using these topical products will enjoy comfortable and convenient dosing.”